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T here are increasing evidences that diabetes mellitus (DM) predisposes to cognitive dysfunctions in animal models and humans with both Type 1 (T1DM) and Type 2 (T2DM) diabetes [1] [2] [3] . Type 1 diabetic encephalopathy (DE) is likely to increase due to the global increase in the incidence of T1DM and its occurrence especially in younger patients. The molecular pathogenesis of DE, one of the serious complications of diabetes mellitus, is complex and complicated [4, 5] . Many mechanisms are involved in DE development therefore treatment is directed on improvements of cellular doi: https://doi.org/10.15407/ubj91.01.021 processes which can be potential targets and searching of new therapeutic strate gies. Development of diabetic encephalopathy is associated with a complex interplay between neurons, glia and vascular components of the brain. However, the precise molecular mechanisms, underlying development of diabetes-induced brain dysfunctions are not completely elucidated. Numerous evidences including our investigations suggest that activation and/or overexpression of poly(ADP-Ribose)polymerase-1 (PARP-1) in the brain and the retina of diabetic rats in response to excessive DNA damage induce cell death [6, 12] . Moreover, under apoptosis, PARP-1 is cleaved by activated caspase-3 and such limited proteolysis of PARP-1 through this split lead to the enzyme inactivation that further facilitates apoptotic cell death [7] . It is strongly believed that PARP-1 inhibitors to be important factors leading to protection of pathological events in diabetic neuropathy [8, 9] . Indeed, we have shown that PARP-1 inhibitors reduce inflammation and production of reactive oxygen species (ROS) that activate an apoptotic death program and may contribute to neurodegeneration [10] . Moreover, an additional hallmark of astroglial reactivity is enhanced expression of glial fibrillary acidic protein (GFAP), a major constituent of astrocyte cytoskeleton. GFAP is responsible for morpholo gy support of hypertrophic astrocytes and involved in other glial functional alterations aimed to protect neurons against harmful effects [11] .
Thus, possible non-invasive treatment strategy of DE would be aimed to improve expression of NAD-dependent proteins such as special proteins, endogenous deacetylases (SIRT, Silent Information Regulators). Almost in all organisms including bacteria, plants and animals are present NAD-dependent sirtuins [16] . For specialized cells the functioning of the genes that express the proteins necessary for the specific functions of one or another tissue is inherent. Silencing of genes provide sirtuins which belong to the class III histone deacetylases. Noteworthy that mammalian sirtuins are highly regulated at the posttranscriptional level, but at the same time they are also transcriptionally regulated [15] . It is believed that SIRT1 could be a vital mediator providing reduction of calorie intake without malnutrition that is very important for diabetic patients [17] [18] [19] [20] [21] [22] . In the nucleus SIRT1 modulates chromatin structure by deacetylating specific lysine residues in histones H1, H3 and H4 [23] . Interestingly enough, that in mammals all seven sirtuins, which are homologs to yeast Sir2, have not only a highly conserved NAD-bin ding site, but also common catalytic core domain and may act as a mono-ADP-ribosyl transferases and/ or NAD-dependent deacetylases. Despite of SIRT2 was originally described as a cytosolic sirtuin recent findings reveal that it also localized in the nucleus where it regulates cell cycle [28, 29] . SIRT1 functions more investigated in liver, heart, white adipose tissue and skeletal muscle, where it inhibits glycolysis [30] .
PARP-1 inhibitors are thought to be ones of the promising approaches to improve brain dysfunctions, because their target is PARP-1 and possibly can be sirtuins. That is why it was important to assess possible positive effects of PARP-1 inhibitors on level sirtuins expression in diabetes mellitus that has not been yet completely investigated. Previously, we have revealed that the amide form of vitamin B 3 (nicotinamide, NAm) and its derivative, N-methylnicotinamide exert pronounced neuroprotective action and ameliorates diabetes-induced diabetic encephalopathy [12, 13] . Our observations, as well as those of other authors, indicate that 1, 5-isoquinolinediol (ISO), potent inhibitor of inducible nitric oxide synthase (iNOS; NOS II) in mouse macrophages and PARP, has the ability to prevent intensification of angiogenesis in some types of retinopathies [40, 44] .
Sirtuins have been involved in key cellular processes, such as cell survival and cell cycle regulation, apoptosis, gene expression control, DNA repair, genome stability stress response, and autophagy [14] . Nevertheless at present very little it is known about role of all sirtuins in the nervous system.
The purpose of present study was to examine the effects of PARP-1 inhibitors, 1.5-isoquinolinediol (ISO) and nicotinamide (NAm), on the expression of SIRT1 and SIRT2 proteins in brain of diabetic rats. materials and methods chemicals and experimental design. All chemicals used were of analytical reagent grade quality and purchased from Sigma Chemical Co. (USA), except for those specified in the text. All procedures fulfilled in accordance with international guidelines and laws for the use and care of laboratory animals and are ethically acceptable. The experiments were performed on male Wistar rats (250-340 g of b.w.), which were maintained in a temperature-and lightcontrolled facility. Rats were fed a standard diet for 12 weeks and had free access to food and water. After 1 week of acclimation, diabetes was induced by a single intraperitoneal (i.p.) injection of freshly prepared solution of streptozotocin (STZ) in citrate buffer, pH 4.5 at a dose 70 mg/kg b.w. Rats of the control group of the same weight, gender and age were intraperitoneally injected only with 0.5 ml of citrate buffer. The animals were maintained on 12-h light/dark cycle and randomly divided into the following groups (n = 5 in each group): control rats (Control); diabetic rats (Diabetes, D); diabetic rats after 10 weeks of diabetes were treated by i.p. injection with 1,5-isoquinolinediol (D + ISO) or with nicotinamide (D + NAm) at doses 3 and 100 mg/kg b. w., respectively, daily for 2 weeks. The dose levels of these compounds and treatment period were chosen on the basis of absence their toxic effects. The rats with blood glucose levels over 19.7 ± 2.1 mmol/l were taken into experiments. During the study period body weight and blood glucose were recorded weekly and then in the end of experiments. After 12 weeks experimental rats after a fasting (12 hours) were sacrificed via cervical dislocation under mild diethyl ether narcosis and blood was collected from the retrobulbar venous sinus of the eye. Blood glucose levels were determined using Precision Xtra Plus (MediSense UK Ltd., Great Britain).
Fractioning and separation of brain nuclear proteins. Whole brain tissue immediately was frozen in liquid nitrogen and сrushed. Then to 100 mg of the сrushed brain tissue was added 0.5% solution of NP40-PBS containing a mixture of protease inhibitors and phosphatase (Thermo Scientific, USA) for lysis of the cell membranes. The homogenate was stored at 4 °C for 20 min [37] . The nuclear extracts of brain tissue were obtained as we described already [10] . A 5×Laemmli sample buffer was added to the interphase (nuclear fraction of proteins) and boiled for 5 min. The samples were stored at -80 °C before analysis.
electrophoresis of proteins in polyacrylamide gel (PaaG) . Electrophoresis of proteins was performed during 3-4 h in PAAG (8-10%) in the presence of 0.1% SDS, using a chamber for electrophoresis, Mini-PROTEAN II (BIO-RAD, Sweden) [38] for subsequent immunoblotting analysis. The molecular mass of proteins in electrophoregrams was determined using standards of proteins obtained from Thermo Scientific (USA) and Fermentas (Lithuania).
Immunoblotting of proteins. Blotting of proteins from PAAG on a nitrocellulose membrane (GE Healthcare, Great Britain) was performed on a Mini Trans-Blot Cell device (BIO-RAD, Sweden) at a voltage of 100 V during 90 min. At the end of the process, the membrane was stained during 5-10 min with 1% solution of the Ponceau S dye, prepared on a 3% solution of trichloroacetic acid. Then, free binding sites on the membrane were blocked during 60 min by a 5% solution of skimmed milk powder (APEX Research, USA) in PBS buffer with the addition of 0.1% Tween-20 (PBSt). Subsequently, the membrane was incubated with primary antibodies in the buffer for blocking overnight at 4 °C; this was followed by washing off with PBSt (three times for 5 min). As secondary antibodies, anti-mouse or anti-rabbit IgGs, conjugated with horseradish peroxidase, in dilutions 1:10 000 and 1:1000 in the blocking buffer , respectively, were used. Incubation with secon dary antibodies was carried out for 60 min at room temperature, and then the membrane was washed off with PBSt three times for 5 min. The following antibodies were used in the study: anti-Poly (ADP-ribose) (Trevigen, USA), anti-β-Actin-Peroxidase (Sigma, USA), anti-SIRT1 (Cell Signaling Technolo gy, USA), anti-SIRT2 (Cell Signa ling Technology, USA), anti-mouse IgG (Sigma, USA) and anti-rabbit IgG (Sigma, USA). Immunoreactive zones were detected by measuring the intensity of chemiluminescence [16] . The densitometric analysis was performed using TotalLab TL120 (Nonlinear Inc., USA) software. The protein contents are shown below in arbitrary units (a.u.).
The values of free NAD/NADH couples ratios were calculated from the concentrations of the metabolites (lactate, pyruvate), taking into account the equilibrium constants of the corresponding dehydrogenase systems [39] .
Measurement of the proteins content in the samples. Proteins content in the samples was estimated by the Bradford technique [41] .
Statistical analysis. Protein contents evaluated by Western blots are expressed in arbitrary units (a.u.) and presented in histograms as mean ± standard error of the mean (SEM). Quantitative results were analyzed by one-way analysis of variance (ANOVA) followed by Bonferroni post-hoc tests. P values < 0.05 were considered to indicate statistical significance. Each determination was performed at least in triplicate.
results and discussion
Development of diabetes was accompanied by increase of blood glucose level and body weight loss. It was shown that after 12 weeks of diabetes the average body weight was 1.34 times lower (263 ± 21 vs. 353 ± 32 g, P < 0.05) than that of control group while blood glucose level was elevated (19.7 ± 2.1 vs. 5.2 ± 0.4 mmol/l, P < 0.05), this is mean that single STZ injections induced the development of strong uncompensated hyperglycemia. Chronic treatment of diabetic rats with ISO or NAm affected neither body weight nor blood glucose level as compared with untreated diabetic animals. Western blot analysis demonstrated significant down-regulation of SIRT1 expression in brain nuclei of diabetic rats compared to non-diabetic group (Fig. 1 ).
The reduction in the level of SIRT1 expression in brain of diabetic rats may indicate a violation of its regulatory effect on posttranslational modification of histone and non-gistone proteins in response to cellular stress induced by T1DM, as well as on the process of neuronal precursor cells differentiation. According to literature data activation of SIRT1 expression can have benefitial effect on brain neurons because its activation protects neurons against β-amyloid-induced toxicity via inhibition of NF-κB Fig. 1 A signalling in microglia [42] . However administration of PARP-1 inhibitors to diabetic rats demonstrated that while ISO had virtually no effect on the expression of SIRT1, NAm slightly increased its expression (Fig. 1) . Nevertheless, slight influence of NAm on increasing SIRT1 expression can have protective effect on metabolic processes in brain, altered by T1DM, resulting in a life prolongation [43] . Noteworthy that such slight effect of NAm on SIRT1 expression in the nuclei extracts of brain tissue can be the result of the fact that SIRT1 is not only localized in the nucleus, where it deacetylates histones thereby influencing genes expression [26] , but SIRT1 can also shuttle to cytoplasm and through this nucleocytoplasmic mechanism may participate in differentiation and in inhibition of cell death [27] . Moreover, sirtuins are structurally different with regard to their N-and C-ends, their sub-cellular localization, and their different substrates [24, 25] . It is not excluded that even slight elevation of SIR1expression in turn can lead to activation of 5′-AMP-activated protein kinase which controls energy intake under physiological and pathological conditions [45] . According to literature data SIRT1 activation can be involved in mitochondrial metabolism in conditions of PARP-1 inhibition [36] . So, the data concerning overexpressing SIRT1 in the brain of rats may provide valuable clues as to how SIRT1 realizes its neuroprotective action in vivo. It is known that SIRT1 in the heart increases ischemic tolerance via an activation of eNOS [31] and it also protects against cardiac hypertrophy through PPARα activation [32] . These data suggest that SIRT1 alterations expression in brain induced by diabetes might impact on encephalopathy develop ment. At the same time, more than a three-fold increase in the content of NAD-dependent SIRT2 deacetylase in diabetic groups was detected compared to control (Fig. 2) , whose elevated content is one of the earliest markers of neurodegenerative processeses development in brain [33] . SIRT2 overexpression can be related to the cell cycle in brain and may be responding on DNA damage induced by diabetes because both deacetylase and mono-ADP-ribosyl tranferase activities have been detected for SIRT2 [24, 35] . It is mean that SIRT 2 acts as a mitotic check point, which, during mitosis, is shuttled from its location in the cytoplasm to the nucleus and may therefore be that SIRT 2 direct inhibits replication [53] . Moreover, the high level of SIRT2 expression in brain can indicate that it may play a role in sensory perception [34] . However it is still considerable work to be done to determine the precise role of SIRT2 in the initiation and progression of brain dysfunctions induced by diabetes in vivo. Diabetic rats treated by ISO had no changes in SIRT2 expression in brain cell nuclei as compared to untreated animals (Fig. 2) , whereas after NAm administration to diabetic rats its expression was slightly decreased, P < 0.05. Therefore, it is not excluded, that exist the connection between the regulatory process under diabetes and level of sirtuins expression in nuclei brain. So, it is mean that sirtuins can become pharmaceutical targets for their modulation and modification. These findings concerning SIRT1 up-regulation and SIRT2 down-regulation are complementary to our previous study showing that PARP-1 inhibition in rats by ISO and NAm increased nicotinamide adenine dinucleotide (NAD + ) content and improved brain functions [10] . However, the molecu lar role of sirtuins in diabetes still remains completely unclear. To better understand of sirtuin functions we have to determine the complete range of their biochemical and enzymatic activities. It should be noted that despite of the fact that ISO did not influence on SITR1 and SIRT2 expression of nuclei brain the protective mechanism of its action on dia betes-induced brain dysfunction might be realized through its influence on other molecular prosesses in brain. As example ISO can inhibit lipid peroxidation, improve the acetylcholinesterase functio ning and partially normalize the levels of GABA and glutamate in the hippocampus [54] . Since PARP-1, SIRT1 and SIRT2 are NADdependent, it is quite obvious that they can compete for the availability of NAD + , reducing not only its content, but also the ratio of free NAD/NADH couples in cells. That is why it was reasonable to evaluate the ratio of free NAD/NADH couples in the brain because it reflects the metabolic state of oxidized and reduced substrates, that is related to two aspects of cellular metabolism: determination the direction of reverse reactions and assessment of alterations of free ener gy in extracellular oxidoreduction (for exam ple, transport of electrons from NADH to flavoproteins in the electron transport chain [55] . As it is known NAD + plays important role in cellular metabolism and realized its action involving in different a key processes including redox reactions which are regulators of cells functioning [46, 47] . Noteworthy, even insignificant changes in metabolism are accompanied by changes in the free NAD/NADH couples ratio, which in turn causes a change in the flow of carbon to the glycolysis or gluconeogenesis at the level of the glyceral dehyde-3-phosphate dehydrogenase reaction [48] . Results obtained in our previously published data revealed that the NAD + content in brain of diabetic rats was reduced [10] . That is why it is not excluded that the ratio of free NAD/ NADH couples also will be changed whereas its maintenance is very important. Indeed, we observed the alterations of metabolites equilibrium concentrations which lead to the reduction of the ratio of free NAD/NADH couples in the brain of diabetic rats to 60.1 versus 186.2 in the control (Fig. 3) . Such changes in the oxidation-reduction state can lead to disturbances in the dynamic equilibrium between the oxidation of glucose in NAD-dependent glycolysis and the NADPH-dependent pentose phosphate pathway and enhance DE develop ment.
It was shown that administration of ISO or NAm to diabetic rats lead to slight increase the ratio of free NAD/NADH couples in the brain to 73.4 in case of ISO and more profound for NAm up to 107.5, that may result in the enhanced fuel oxidation and amplification of NAD + -dependent SIRT-1 pathway in brain, leading to the improvement of insulin sensitivity and glucose homeostasis. It should be noted that our findings are consistent with results concerning Parkinson's disease that does not exclude the common mechanisms of neurodegenerative processes development in the nervous system [52] .
In conclusion, it is becoming clear that both SIRT1 and SIRT2 play an important role in brain functioning and alterations of their expression induced by diabetes lead to brain dysfunctions which can be accompanied by cognitive impairment develop ment. However, the results of the present study have shown that among investigated PAPR-1 inhibitors only NAm can partially ameliorate sirtuins expression and improve redox state in brain of diabetic rats. Unlike ISO, anti-diabetic efficacy of NAm may also be associated with formation of 1-methylnicotinamide, one of the endogenous products of NAm, due to its ability to attenuate deleterious effects of diabetes in the CNS as we observed erlier [13] . We also emphasize here that the inhibition of PAPR-1 may be linked with improvement of SIRT1 and SIRT2 functioning during hyperglycemia, possibly due to influence of NAm on the sirtuins expression. More importantly, our results indicate the need to develop more specific modulators of these sirtuins that would not cause any side effects. Therefore these sirtuins can be promising and potential therapeutic targets for treatment of diabetic encephalopathy. Молекулярні механізми патогенезу діабетичної енцефалопатії (ДЕ), одного із серйоз-них ускладнень цукрового діабету, є складними. У цій роботі досліджували експресію SIRT1 та SIRT2 як ключову в розвитку дисфункції мозку та можливість інгібіторів PARP-1 впливати на експресію цих протеїнів з метою попереджен-ня розвитку ДЕ в щурів із діабетом 1-го типу. Через 10 тижнів розвитку цукрового діабету, індукованого стрептозотоцином (70 мг/кг), щурам-самцям лінії Wistar вводили інгібітори PARP-1, 1,5-ізохіноліндіол (ISO) або нікотинамід (NAm) (3 або 100 мг/кг/добу відповідно) про-тягом 2 тижнів. В експерименти були взяті щури із рівнем глюкози в крові більше 19,7 ± 2,1 ммоль/л. Вестерн-блот аналіз був проведений для оцінки впливу інгібіторів PAPR-1 на рівні експресії SIRT1 та SIRT2. Діабет призводив до значного зниження експресії SIRT1 та надмірної експресії SIRT2 в ядерних екс трактах мозку діабетичних щурів порівняно з недіабетичним контролем. Введення NAm пригнічувало надмірну експресію SIRT2 в ядерних екстрактах мозку в діабетичних щурів і незначною мірою підвищував експресію SIRT1, тоді як ISO не впливав на експресію обох сиртуїнів. Більше того, виявлено, що в мозку діабетичних щурів співвідношення вільних NAD/NADH пар було в 3,1 раза нижче порівняно з недіабетичним контролем. Застосування ISO спричинювало незначне збільшення співвідношення вільних NAD/NADH пар у мозку діабетичних щурів, тоді як NAm збільшував цей показник у 1,7 раза порівняно з діабетичними щурами. Одержані дані свідчать про те, що зміни експресії SIRT1 і SIRT2 в ядрах клітин мозку діабетичних щурів можуть призводити до розвитку дисфункцій мозку. Один з нейропротекторних механізмів дії NAm також може бути реалізований шляхом гальмування експресії SIRT2 в ядрах клітин го-ловного мозку, що знижує рівень прогресування індукованих діабетом змін і може бути терапев-тичним засобом для лікування дисфункцій мозку.
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